Edgar G. Engleman

Edgar G. Engleman is a renowned immunologist and pathologist known for his significant contributions to the field of medicine. He is currently serving as a Professor of Pathology and Medicine at Stanford University School of Medicine.

Early Life and Education[edit | edit source]

Edgar G. Engleman was born in New York City. He completed his undergraduate studies at Columbia University, where he developed an interest in biology and chemistry. He then pursued his medical degree from Yale University School of Medicine, where he specialized in immunology and pathology.

Career[edit | edit source]

After completing his medical degree, Engleman joined Stanford University School of Medicine as a faculty member. He has made significant contributions to the field of immunology, particularly in the development of dendritic cell-based cancer immunotherapy. His research has led to the development of several innovative therapies for cancer and other diseases.

Engleman is also the founder of several biotechnology companies, including Dendreon Corporation, which developed the first FDA-approved cancer immunotherapy, and Cellerant Therapeutics, which is developing stem cell and immunotherapy-based treatments for cancer and other diseases.

Research[edit | edit source]

Engleman's research focuses on the role of the immune system in health and disease. He has made significant contributions to our understanding of how the immune system can be harnessed to fight cancer and other diseases. His work on dendritic cells has been particularly influential, leading to the development of new therapies for cancer and other diseases.

Awards and Recognition[edit | edit source]

Engleman has received numerous awards and recognition for his contributions to medicine and science, including the American Association for Cancer Research's Award for Outstanding Achievement in Cancer Research and the American Society of Hematology's Distinguished Service Award.